EANM’11 – CTE Session VI
October 19, 2011, 09:30 – 10:45
Bone Cancer in SPECT/CT and PET/CT
Moderators: C. Pestean (Cluj-Napoca)
Upon completion of this session the attendee will be able to:
- Identify the role of PET/CT in the evaluation of primary or metastatic bone lesions.
- Learn about the type of bone-specific PET tracers or tumour-specific PET tracers used in
- Identify the role of SPECT/CT in the diagnostic algorithm of skeletal lesions in oncology.
- Show the difference between conventional bone scintigraphy augmented with other
diagnostic methods and SPECT/CT as a method of diagnosis.
- Find new directions and new perspectives in diagnostic algorithms and protocols in bone
tumours considering also technetium shortage which was a critical issue in last period of
- Find the limits and the future aspect of hybrid PET/CT bone tumour imaging.
Conventional bone scintigraphy in primary or metastatic bone lesions is an important tool in diagnosis and also in follow-up. But it is associated with low spatial resolution and often with low specificity. Even so bone scintigraphy remains the commonest method for evaluation or follow-up of bone metastatic disease. Due to its limitations, the perspective has changed and the interest for new hybrid methods is incremental.
With the advent of new hybrid methods as SPECT/CT and PET/CT the accuracy of diagnostic process has been increased having a better spatial resolution, a more clear anatomical localization, a higher specificity and sensitivity. The interest for tracers like [(18)F] fluoride (NaF) as a bone-specific tracer, or [(18)F] fluorodeoxyglucose and [(18)F] choline as tumour- specific tracers in diagnosis and follow-up has increased during recent years and are helpful alternatives to technetium-based methods especially at present when technetium shortage may be a critical problem.
It is very important to know how these hybrid methods can improve in a specific way the diagnostic process in bone cancer, even if we consider primary or metastatic lesions.
PET/CT, SPECT/CT, Bone Cancer, [(18)F] Fluoride (NaF), [(18)F] Fluorodeoxyglucose [(18)F] Choline, Bone Metastases